Education
About Us
Working with TipRanks
Follow Us
Arcturus Therapeutics (ARCT)
NASDAQ:ARCT
ARCT Analyst Ratings
Strong Buy
8 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ARCT Stock 12 Month Forecast
Average Price Target
$67.86
▲(467.87% Upside)
| Highest Price Target$140.00 | Average Price Target$67.86 | Lowest Price Target$44.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
BTIG
Reiterated
03/27/25
William Blair
Reiterated
03/13/25
Citigroup
Reiterated
03/13/25
Canaccord Genuity
Reiterated
03/10/25
H.C. Wainwright
Reiterated
03/07/25
Piper Sandler
Reiterated
03/07/25
Wells Fargo
Reiterated
03/07/25
Leerink Partners
Reiterated
03/07/25
Laidlaw
$79
Buy
561.09%
Upside
Reiterated
07/02/24
Laidlaw reiterates Buy Rating on Arcturus Therapeutics (ARCT)Laidlaw analyst Yale Jen reiterated a Buy rating and $79.00 price target on Arcturus Therapeutics (NASDAQ: ARCT).
WBB Securities
$25
Buy
109.21%
Upside
Upgraded
06/30/24
We arrive at our valuation using a sum-of-the-parts model: We assign a per-share value of $10.00 to the Lunar-OTC program and $9.00 to the LUNAR-CF program. And the balance of $6.00 to the different vaccine programs. Thus, we arrive at a 12- month per share price target of $25.00.
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
BTIG
Reiterated
03/27/25
William Blair
Reiterated
03/13/25
Citigroup
Reiterated
03/13/25
Canaccord Genuity
Reiterated
03/10/25
H.C. Wainwright
Reiterated
03/07/25
Piper Sandler
Reiterated
03/07/25
Wells Fargo
Reiterated
03/07/25
Leerink Partners
Reiterated
03/07/25
Laidlaw
$79
Buy
561.09%
Upside
Reiterated
07/02/24
Laidlaw reiterates Buy Rating on Arcturus Therapeutics (ARCT)Laidlaw analyst Yale Jen reiterated a Buy rating and $79.00 price target on Arcturus Therapeutics (NASDAQ: ARCT).
WBB Securities
$25
Buy
109.21%
Upside
Upgraded
06/30/24
We arrive at our valuation using a sum-of-the-parts model: We assign a per-share value of $10.00 to the Lunar-OTC program and $9.00 to the LUNAR-CF program. And the balance of $6.00 to the different vaccine programs. Thus, we arrive at a 12- month per share price target of $25.00.
ARCT Analyst Recommendation Trends
Rating
Nov 24
Dec 24
Jan 25
Feb 25
Mar 25
Strong Buy
9
6
12
14
19
Buy
5
4
4
3
4
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
14
10
16
17
23
Each month's total comprises the sum of three months' worth of ratings.
ARCT Financial Forecast
ARCT Stock Forecast FAQ
What is ARCT’s average 12-month price target, according to analysts?
Based on analyst ratings, Arcturus Therapeutics’s 12-month average price target is $67.86.
What is ARCT’s upside potential, based on the analysts’ average price target?
Arcturus Therapeutics has 467.87% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ARCT a Buy, Sell or Hold?
Arcturus Therapeutics has a consensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.
What is Arcturus Therapeutics’s price target?
The average price target for Arcturus Therapeutics is $67.86. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $140.00 ,the lowest forecast is $44.00. The average price target represents 467.87% Increase from the current price of $11.95.
The highest analyst price target is $140.00 ,the lowest forecast is $44.00. The average price target represents 467.87% Increase from the current price of $11.95.
What do analysts say about Arcturus Therapeutics?
Arcturus Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
How can I buy shares of ARCT?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.